PDD 00031705

Pricing Availability   Qty
Description: Negative control for PDD 00017238 (Cat. No. 7007)
Chemical Name: 1-[(2,4-Dimethyl-5-thiazolyl)methyl]-2,3-dihydro-N-methyl-N-(1-methylcyclopropyl)-2-oxo-3-(1,2,4-thiadiazol-5-yl)-1H-benzimidazole-5-sulfonamide
Purity: ≥98% (HPLC)
Citations (1)
Literature (1)

Biological Activity for PDD 00031705

PDD 00031705 is a negative control for PDD 00017238 (Cat. No. 7007).

Technical Data for PDD 00031705

M. Wt 490.62
Formula C20H22N6O3S3
Storage Store at -20°C
Purity ≥98% (HPLC)
CAS Number 2032096-45-8
PubChem ID 123131658
Smiles CN(S(=O)(C1=CC=C2N(C(N(C2=C1)C3=NC=NS3)=O)CC4=C(N=C(S4)C)C)=O)C5(CC5)C

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for PDD 00031705

Solvent Max Conc. mg/mL Max Conc. mM
DMSO 4.91 10

Preparing Stock Solutions for PDD 00031705

The following data is based on the product molecular weight 490.62. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
0.1 mM 20.38 mL 101.91 mL 203.82 mL
0.5 mM 4.08 mL 20.38 mL 40.76 mL
1 mM 2.04 mL 10.19 mL 20.38 mL
5 mM 0.41 mL 2.04 mL 4.08 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

References for PDD 00031705

References are publications that support the biological activity of the product.

James et al (2016) First-in-class chemical probes against poly(ADP-ribose) glycohydrolase (PARG) inhibit DNA repair with differential pharmacology to Olaparib. ACS Chem.Biol. 11 3179 PMID: 27689388

If you know of a relevant reference for PDD 00031705, please let us know.

View Related Products by Product Action

View all Poly(ADP-ribose) Glycohydrolase Controls

Keywords: PDD 00031705, PDD 00031705 supplier, PDD00031705, poly, ADP, ribose, glycohydrolase, PARG, inhibitors, negative, controls, Poly(ADP)-ribose, Glycohydrolase, 7009, Tocris Bioscience

1 Citation for PDD 00031705

Citations are publications that use Tocris products. Selected citations for PDD 00031705 include:

Craig A et al (2018) Hypoxia induces pulmonary fibroblast proliferation through NFAT signaling. Sci Rep 8 2709 PMID: 29426911

Do you know of a great paper that uses PDD 00031705 from Tocris? Please let us know.

Reviews for PDD 00031705

There are currently no reviews for this product. Be the first to review PDD 00031705 and earn rewards!

Have you used PDD 00031705?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.

Epigenetics in Cancer Poster

Epigenetics in Cancer Poster

This poster summarizes the main epigenetic targets in cancer. The dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible and thus make promising therapeutic targets.